<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954198</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00059602</org_study_id>
    <nct_id>NCT02954198</nct_id>
  </id_info>
  <brief_title>Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients</brief_title>
  <official_title>Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the availability of well-studied once-daily formulations of tacrolimus, the ability to
      achieve a true once-daily immunosuppressant regimen along with everolimus and steroids may
      finally be achievable and have the potential to optimize immunosuppression safety and
      efficacy in kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A once-daily immunosuppressant regimen comprising of Envarsus-everolimus-prednisone will have
      6-month treatment failure rates that are non-inferior to the twice-daily regimen of
      Envarsus-mycophenolate mofetil-prednisone and will have improved patient-reported adherence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence Superiority</measure>
    <time_frame>6 months post conversion</time_frame>
    <description>Estimate change from baseline to six months in adherence superiority measure by MMAS-8 in patients converted to a once-daily immunosuppressant regimen of Envarsus®, everolimus, and prednisone versus patients converted to a twice-daily regimen of Envarsus® (once daily), MMF (twice daily), and prednisone (once daily).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure Rate</measure>
    <time_frame>Baseline to 6 months post conversion</time_frame>
    <description>Estimate the composite of treatment failure rate, defined as acute allograft rejection with a Banff grade 1A or higher, graft loss, or death at six months post-conversion, in patients converted to a once-daily immunosuppressant regimen of Envarsus®, everolimus, and prednisone versus patients converted to a twice-daily regimen of Envarsus®, MMF, and prednisone.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject Specific Change of Memphis Medication Side Effect Scale</measure>
    <time_frame>Baseline to 6 months post conversion</time_frame>
    <description>Examine subject specific change of the Memphis Medication Side Effect Scale at the time of the conversion versus six months post-conversion, compared between the two arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Death</measure>
    <time_frame>Baseline to 6 months post conversion</time_frame>
    <description>Measure and compare time-to-event analysis between the two arms patient death (time to event analysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Biopsy Proven Acute Rejection</measure>
    <time_frame>Baseline to 6 months post conversion</time_frame>
    <description>Measure and compare time-to-event analysis between the two arms patient death (time to event analysis).</description>
  </other_outcome>
  <other_outcome>
    <measure>Graft Loss</measure>
    <time_frame>Baseline to 6 months post conversion</time_frame>
    <description>Measure and compare time-to-event analysis between the two arms graft loss (time to event analysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Medication Possession Ratio</measure>
    <time_frame>Baseline to 6 months post conversion</time_frame>
    <description>Examine the medication possession ratio (MPR) of adjunctive immunosuppressants (Everolimus or mycophenolate) during follow up between the two arms and compare the prevalence of patients with MPR &gt;80%</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline to 6 months post conversion</time_frame>
    <description>Compare rates of adverse events and severe adverse events between the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Rejection</measure>
    <time_frame>3 month to one year post conversion</time_frame>
    <description>Perform exploratory analysis of subclinical rejection and IF/TA in patients with one year protocol biopsies as compared to three month protocol biopsies between the two arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Tacrolimus + MMF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Envarsus + Everoliumus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>goal trough level 5-12ng/mL</description>
    <arm_group_label>Tacrolimus + MMF</arm_group_label>
    <arm_group_label>Envarsus + Everoliumus</arm_group_label>
    <other_name>Envarsus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>goal dose 5mg QD</description>
    <arm_group_label>Tacrolimus + MMF</arm_group_label>
    <arm_group_label>Envarsus + Everoliumus</arm_group_label>
    <other_name>Corticosteroids</other_name>
    <other_name>Methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>goal dose 1g BID</description>
    <arm_group_label>Tacrolimus + MMF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>goal trough level 3-8ng/mL</description>
    <arm_group_label>Envarsus + Everoliumus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion criteria

          1. Male or female adult (≥18 years old) with a history of solitary kidney transplant
             within 3 months (±2 months) of transplant with self-reported medication adherence
             issues, as indicated by a MMAS-8 of at least 1.

          2. Patients must be capable of understanding the purposes and risks of the study and have
             the ability to give written informed consent and be willing to participate and comply
             with the study.

          3. Women of childbearing potential must have a negative pregnancy test within the 48
             hours prior to receiving study medication.

          4. Women of childbearing potential and sexually active males must be willing to use
             contraception, as indicated in Section 6 of the protocol. Subjects who are not of
             reproductive potential (status post bilateral tubal ligation, bilateral oophorectomy,
             hysterectomy, or vasectomy), not sexually active, whose current partner(s) is not of
             reproductive potential, or whose sexual activity is exclusively homosexual are
             eligible without requiring the use of contraception.

        2. Exclusion criteria

          1. Patients will be excluded if they are pregnant or nursing females or males with a
             pregnant female partner

          2. Recipient of multiple organ transplant

          3. Recipient of a non-renal organ

          4. Proteinuria &gt; 800 mg/24 hour

          5. eGFR &lt; 30 ml/min

          6. WBC ≤ 2k/mm3

          7. Plt ≤ 50k/mm3

          8. Triglycerides &gt; 500 mg/dL

          9. HIV positive (HIV ab +)

         10. Unable to tolerate oral medications

         11. Use of another investigational product within thirty days prior to receiving study
             medication

         12. Acute graft rejection within the past month (Banff 1A or higher) or received an ABO
             incompatible donor organ.

         13. A condition or disorder that, in the opinion of the investigator, may adversely affect
             the outcome of the study or the safety of the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mackenzie Fraser</last_name>
    <phone>843-792-8896</phone>
    <email>fraserm@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taber, PharmD</last_name>
      <phone>843-792-4003</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

